Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors

Morten Hansen; Kristine Juul Hare; Jens Juul Holst; Filip Krag Knop

Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors

Morten Hansen, Kristine Juul Hare, Jens Juul Holst, Filip Krag Knop

Abstract

Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to current
antidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type
2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines the
role of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), and
gives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagon
data from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptor
agonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasma
glucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.

Originalsprog	Engelsk
Tidsskrift	Journal of Clinical Metabolism & Diabetes
Vol/bind	2
Udgave nummer	2
Sider (fra-til)	7-13
Antal sider	7
ISSN	2041-8019
Status	Udgivet - jun. 2011

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

@article{7a83e000596245738080e59d412a8666,

title = "Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors",

abstract = "Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to currentantidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines therole of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), andgives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagondata from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptoragonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasmaglucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.",

author = "Morten Hansen and {Juul Hare}, Kristine and Holst, {Jens Juul} and Knop, {Filip Krag}",

year = "2011",

month = jun,

language = "English",

volume = "2",

pages = "7--13",

journal = "Journal of Clinical Metabolism & Diabetes",

issn = "2041-8019",

publisher = "San Lucas Medical",

number = "2",

}

TY - JOUR

T1 - Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors

AU - Hansen, Morten

AU - Juul Hare, Kristine

AU - Holst, Jens Juul

AU - Knop, Filip Krag

PY - 2011/6

Y1 - 2011/6

N2 - Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to currentantidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines therole of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), andgives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagondata from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptoragonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasmaglucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.

AB - Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to currentantidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines therole of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), andgives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagondata from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptoragonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasmaglucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.

M3 - Journal article

SN - 2041-8019

VL - 2

SP - 7

EP - 13

JO - Journal of Clinical Metabolism & Diabetes

JF - Journal of Clinical Metabolism & Diabetes

IS - 2

ER -

Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors

Abstract

FN’s Verdensmål

Fingeraftryk

Citationsformater